The latest news from academia, regulators
research labs and other things of interest
Posted: May 28, 2009
Nanosphere to Release Three Abstracts At American Society of Clinical Oncology (ASCO) 2009 Annual Meeting
(Nanowerk News) Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it will provide cancer related data through three abstracts at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Orlando, Fla. from May 29 to June 2, 2009. The abstracts discuss the use of biomarkers in pre-clinical development, cancer recurrence and clinical needs of novel biomarkers.
Abstract ID: e14594 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Ultra-Sensitive detection of biomarkers and applications in pharmaceutical discovery and development. Example application to rat Cardiac troponin I assay via nanoparticle probes."
Verisens™ cTnI Cardiotoxicity Assay is an in vitro diagnostic assay for the high-sensitivity detection and quantification of rat cardiac troponin I (cTnI). The assay is intended to be performed as a testing service for research use only.
For additional information, please contact Nanosphere at email@example.com
Abstract ID: e16146 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay."
Verisens™ PSA is an in vitro diagnostic assay for the high-sensitivity detection and quantification of prostate specific antigen (PSA). The assay was developed in collaboration with the International Institute for Nanotechnology at Northwestern University. It is intended to be performed as a testing service for research use only (see research-use notification below).
For additional information, please contact Nanosphere at firstname.lastname@example.org
Abstract ID: e22222 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Biomarkers in cancer: Survey of diagnostic needs."
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.